ES3048688T3 - High dosage strength tablets of rucaparib - Google Patents
High dosage strength tablets of rucaparibInfo
- Publication number
- ES3048688T3 ES3048688T3 ES15833096T ES15833096T ES3048688T3 ES 3048688 T3 ES3048688 T3 ES 3048688T3 ES 15833096 T ES15833096 T ES 15833096T ES 15833096 T ES15833096 T ES 15833096T ES 3048688 T3 ES3048688 T3 ES 3048688T3
- Authority
- ES
- Spain
- Prior art keywords
- tablet
- rucaparib
- tablet according
- tablets
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040849P | 2014-08-22 | 2014-08-22 | |
| US201562101739P | 2015-01-09 | 2015-01-09 | |
| PCT/US2015/045522 WO2016028689A1 (en) | 2014-08-22 | 2015-08-17 | High dosage strength tablets of rucaparib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3048688T3 true ES3048688T3 (en) | 2025-12-11 |
Family
ID=55347324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15833096T Active ES3048688T3 (en) | 2014-08-22 | 2015-08-17 | High dosage strength tablets of rucaparib |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9987285B2 (enExample) |
| EP (1) | EP3182975B1 (enExample) |
| JP (3) | JP6574477B2 (enExample) |
| KR (2) | KR20170043597A (enExample) |
| CN (2) | CN106794185A (enExample) |
| AU (2) | AU2015305696B2 (enExample) |
| BR (1) | BR112017000865A2 (enExample) |
| CA (1) | CA2955495C (enExample) |
| DK (1) | DK3182975T3 (enExample) |
| ES (1) | ES3048688T3 (enExample) |
| FI (1) | FI3182975T3 (enExample) |
| HR (1) | HRP20251484T1 (enExample) |
| IL (1) | IL249946B (enExample) |
| LT (1) | LT3182975T (enExample) |
| MX (1) | MX367260B (enExample) |
| NZ (1) | NZ728392A (enExample) |
| PL (1) | PL3182975T3 (enExample) |
| PT (1) | PT3182975T (enExample) |
| RS (1) | RS67356B1 (enExample) |
| RU (1) | RU2705156C2 (enExample) |
| SG (1) | SG11201700265VA (enExample) |
| SI (1) | SI3182975T1 (enExample) |
| WO (1) | WO2016028689A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| HK1232218A1 (zh) | 2014-02-05 | 2018-01-05 | Merck Sharp & Dohme Llc | Cgrp-活性化合物的片剂制剂 |
| DK3182975T3 (da) * | 2014-08-22 | 2025-10-20 | Pharma& Schweiz Gmbh | Tabletter med høj doseringsstyrke af rucaparib |
| CN106008530B (zh) * | 2016-07-24 | 2018-06-26 | 石家庄久正生物科技有限公司 | 一种抗卵巢癌药物Rucaparib关键中间体的制备方法 |
| CN108201534A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种瑞卡帕布口服缓控释药物组合物及其用途 |
| ES2985767T3 (es) | 2017-01-24 | 2024-11-07 | Assia Chem Ind Ltd | Formas en estado sólido de rucaparib y de sales de rucaparib |
| EP3600314A1 (en) | 2017-03-27 | 2020-02-05 | Tesaro, Inc. | Niraparib compositions |
| CA3076907A1 (en) | 2017-09-26 | 2019-04-04 | Tesaro, Inc. | Niraparib formulations |
| WO2019130229A1 (en) | 2017-12-28 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing rucaparib |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US12090148B2 (en) | 2020-07-29 | 2024-09-17 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN109111454A (zh) * | 2018-08-01 | 2019-01-01 | 宁波金未生物科技有限公司 | 一种瑞卡帕布s-樟脑磺酸盐 |
| CN108853030B (zh) * | 2018-09-26 | 2021-10-01 | 上海朝晖药业有限公司 | 一种治疗恶性肿瘤的药物制剂及其制备方法 |
| CN111542527A (zh) * | 2018-12-06 | 2020-08-14 | 上海诚妙医药科技有限公司 | 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途 |
| MY209459A (en) | 2019-07-10 | 2025-07-09 | Cybrexa 3 Inc | Peptide conjugates of microtubule-targeting agents as therapeutics |
| CA3146560A1 (en) | 2019-07-10 | 2021-01-14 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| KR20230002487A (ko) | 2020-04-28 | 2023-01-05 | 리젠 파마슈티컬스 아게 | 폴리(adp-리보스) 폴리머라제(parp) 억제제로서 유용한 신규 화합물 |
| HRP20251324T1 (hr) | 2020-07-14 | 2025-12-05 | Assia Chemical Industries Ltd. | Oblici soli rukapariba u krutom stanju |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| WO2022140537A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| BR112023020615A2 (pt) | 2021-04-08 | 2023-12-19 | Incozen Therapeutics Pvt Ltd | Inibidores de poli(adp-ribose) polimerase |
| AU2022353124A1 (en) | 2021-09-27 | 2024-04-11 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
| US11738029B2 (en) * | 2021-11-10 | 2023-08-29 | Crititech, Inc. | Rucaparib particles and uses thereof |
| US20250223295A1 (en) | 2022-01-11 | 2025-07-10 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20010573B1 (en) | 1999-01-11 | 2006-04-30 | Agouron Pharmaceuticals | Tricyclic inhibitors of poly(adp-ribose) polymerases |
| CA2520997A1 (en) | 2003-03-31 | 2004-10-14 | Stacie Sara Canan-Koch | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| ATE454893T1 (de) | 2003-07-25 | 2010-01-15 | Cancer Rec Tech Ltd | Tricyclische parp-hemmer |
| JP2008513436A (ja) | 2004-09-22 | 2008-05-01 | ファイザー・インク | ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンのリン酸塩の多形性及び非晶質形態 |
| PL1794163T3 (pl) | 2004-09-22 | 2010-06-30 | Pfizer | Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy |
| JP2008513435A (ja) | 2004-09-22 | 2008-05-01 | ファイザー・インク | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物 |
| CA2720744A1 (en) * | 2008-04-09 | 2009-10-15 | Lek Pharmaceuticals D.D. | Granulation of active pharmaceutical ingredients |
| RS55487B2 (sr) | 2010-02-12 | 2024-06-28 | Pfizer | Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona |
| PT2833973T (pt) | 2012-04-05 | 2017-12-21 | Vertex Pharma | Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos |
| DK3182975T3 (da) | 2014-08-22 | 2025-10-20 | Pharma& Schweiz Gmbh | Tabletter med høj doseringsstyrke af rucaparib |
-
2015
- 2015-08-17 DK DK15833096.9T patent/DK3182975T3/da active
- 2015-08-17 HR HRP20251484TT patent/HRP20251484T1/hr unknown
- 2015-08-17 SG SG11201700265VA patent/SG11201700265VA/en unknown
- 2015-08-17 SI SI201532081T patent/SI3182975T1/sl unknown
- 2015-08-17 NZ NZ728392A patent/NZ728392A/en unknown
- 2015-08-17 CA CA2955495A patent/CA2955495C/en active Active
- 2015-08-17 PT PT158330969T patent/PT3182975T/pt unknown
- 2015-08-17 CN CN201580042815.9A patent/CN106794185A/zh active Pending
- 2015-08-17 ES ES15833096T patent/ES3048688T3/es active Active
- 2015-08-17 AU AU2015305696A patent/AU2015305696B2/en active Active
- 2015-08-17 EP EP15833096.9A patent/EP3182975B1/en active Active
- 2015-08-17 KR KR1020177007284A patent/KR20170043597A/ko not_active Ceased
- 2015-08-17 KR KR1020237020594A patent/KR102803917B1/ko active Active
- 2015-08-17 LT LTEPPCT/US2015/045522T patent/LT3182975T/lt unknown
- 2015-08-17 MX MX2017001540A patent/MX367260B/es active IP Right Grant
- 2015-08-17 BR BR112017000865A patent/BR112017000865A2/pt not_active Application Discontinuation
- 2015-08-17 PL PL15833096.9T patent/PL3182975T3/pl unknown
- 2015-08-17 WO PCT/US2015/045522 patent/WO2016028689A1/en not_active Ceased
- 2015-08-17 FI FIEP15833096.9T patent/FI3182975T3/fi active
- 2015-08-17 US US14/828,065 patent/US9987285B2/en active Active
- 2015-08-17 RU RU2017109139A patent/RU2705156C2/ru active
- 2015-08-17 JP JP2017510539A patent/JP6574477B2/ja active Active
- 2015-08-17 RS RS20251082A patent/RS67356B1/sr unknown
- 2015-08-17 CN CN202110458329.2A patent/CN113209033A/zh active Pending
-
2017
- 2017-01-05 IL IL249946A patent/IL249946B/en active IP Right Grant
-
2018
- 2018-03-14 US US15/920,643 patent/US10130636B2/en active Active
- 2018-10-08 US US16/154,038 patent/US20190099430A1/en not_active Abandoned
-
2019
- 2019-08-15 JP JP2019149084A patent/JP6797980B2/ja active Active
- 2019-11-29 AU AU2019272064A patent/AU2019272064B2/en active Active
-
2020
- 2020-11-18 JP JP2020191356A patent/JP7127101B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3048688T3 (en) | High dosage strength tablets of rucaparib | |
| EP3606511B1 (en) | Pharmaceutical composition comprising lenvatinib mesylate | |
| KR20140087846A (ko) | 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 | |
| US8951504B2 (en) | (trimethoxyphenylamino) pyrimidinyl formulations | |
| TWI418370B (zh) | 溶出安定性製劑 | |
| US20070172521A1 (en) | Levetiracetam formulations and methods for their manufacture | |
| JP2017520619A (ja) | セリチニブ製剤 | |
| HK1232807A1 (en) | High dosage strength tablets of rucaparib | |
| HK1232807B (en) | High dosage strength tablets of rucaparib | |
| JP2019014700A (ja) | エゼチミブ含有口腔内崩壊錠及びその製造方法 | |
| KR20160085241A (ko) | 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 |